Management of hepatitis C virus in the transplant patient.
Hepatitis C virus (HCV) is a leading cause of chronic hepatitis, with 170 to 190 million people infected worldwide. The treatment of choice for patients who have HCV-related cirrhosis with or without hepatocellular carcinoma is liver transplantation. Virologic recurrence is constant after transplantation and results in chronic hepatitis in the vast majority. HCV infection now can be cured in a substantial proportion of liver transplant recipients. This review highlights the available strategies to improve outcome, including modification of factors that affect disease progression and the efficacy of antiviral therapy.
Berenguer
Marina
M
Universidad de Medicina, Hospital Universitario La Fe, Servicio de Medicina Digestiva, Ciberehd, Avda Campanar 21, Valencia, 46009 Spain. mbhaym@teleline.es
D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016031:Liver Transplantation
D000998:Antiviral Agents; D007155:Immunologic Factors